Overview

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given twice weekly to patients with leukemia or myelodysplastic syndromes.
Phase:
Phase 1
Details
Lead Sponsor:
Mirati Therapeutics Inc.
Treatments:
Mocetinostat